Latest news

• NHS says Humira biosimilar deal will save £300m

  s Cyltezo and Mylan’s Hulio, the latter sublicensed from Japan’s Fujifilm Kyowa Kirin.

• First Humira biosimilars reach EU market

  Meanwhile, a fifth biosimilar called Cyltezo from Boehringer Ingelheim has been approved for sale but its launch has been held up by patent litigation with AbbVie, according to a Financial Times

• Settlement clears path for Biogen, Samsung’s Humira biosimilar

  It’s not the end of the matter entirely, as other Humira biosimilars are coming through development, including Boehringer Ingelheim’s Cyltezo which has been approved in the US and

• Novartis joins biosimilar Humira push in US

  Pharma giant hopes its candidate will follow in the footsteps of Amgen’s Amjevita and BI’s Cyltezo. ... The biosimilar is vying to be the third copycat version of AbbVie’s Humira (adalimumab) in the big US market after Amgen’s Amjevita and

• Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown

  approved biosimilars, including Samsung Bioepis’ Imraldi and Boehringer Ingelheim’s Cyltezo in Europe, and Amgen’s Amgevita as well as Cyltezo in the US.